Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Geoffrey Shouse, DO, PhD, Sylvia O Dulan, RN, Jamie Wagner, BS, Michelle Mott, RN, Alex Ly, Donna Ujiiye, Mary C. Clark, PhD, Kathie Viers, RN, Stephen J. Forman, MD, Eileen P. Smith, MD, David S Snyder, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-143412

Published: 2020

Journal Articles

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert Chen, Joycelynne Palmer, PhD, Peter Martin, MD, Saro Armenian, DO, MPH, Nichun Tsai, Michelle Mott, Firoozeh Sahebi, Ji-Lian Cai, MD PhD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Auayporn P. Nademanee, MD, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 519.

https://doi.org/10.1182/blood.V126.23.519.519

Published: 2015

Journal Articles

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert W Chen, MD, Joycelynne Palmer, PhD, Peter Martin, MD, Nicole Tsai, Young Kim, MD, Michelle Mott, RN, Firoozeh Sahebi, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Tsiporah B. Shore, Stephen J. Forman

Blood (2014) 124 (21): 501.

https://doi.org/10.1182/blood.V124.21.501.501

Published: 2014

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Robert W. Chen, MD, Joycelynne Palmer, PhD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Young Kim, MD, Chen T Binhong, MD, Amrita Krishnan, MD, Nitya Nathwani, MD, Ji-Lian Cai, MD, PhD, Michelle Mott, RN, Deron Matsuoka, BS, Stephen J Forman, MD

Blood (2012) 120 (21): 3699.

https://doi.org/10.1182/blood.V120.21.3699.3699

Published: 2012

NARROW

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Email alerts

ASH Publications

American Society of Hematology

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only